Envelope glycoprotein gp160 · SINGLE PROTEIN · Human immunodeficiency virus 1
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-12Envelope glycoprotein gp160 shows clinical signal disease relevance led by AIDS. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q6QLK5. Start with AIDS, then reuse UniProt Q6QLK5 as the stable protein anchor across project notes and exports.
Start with AIDS, then reuse UniProt Q6QLK5 as the stable protein anchor across project notes and exports.
Envelope glycoprotein gp160 shows clinical signal disease relevance led by AIDS. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with AIDS because it currently carries clinical signal support. Linked drugs include PRO-542. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyEnvelope glycoprotein gp160
Review this target as Envelope glycoprotein gp160, mapped to UniProt Q6QLK5. Sequence length is 814 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Envelope glycoprotein gp160 as ChEMBL target CHEMBL1293311, mapped to UniProt Q6QLK5. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Envelope glycoprotein gp160 is the right protein anchor across sources, using UniProt Q6QLK5 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why AIDS is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Envelope glycoprotein gp160 |
| Target Type | SINGLE PROTEIN |
| Organism | Human immunodeficiency virus 1 |
| UniProt | Q6QLK5 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Envelope glycoprotein gp160 |
| UniProt Accession | Q6QLK5 |
| Component Type | Protein |
| Sequence Length | 814 aa |
Envelope glycoprotein gp160
Review this target as Envelope glycoprotein gp160, mapped to UniProt Q6QLK5. Sequence length is 814 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Envelope glycoprotein gp160 shows clinical signal disease relevance led by AIDS. 1 more disease program remain visible in the same review block.
Start review with AIDS because it currently carries clinical signal support. Linked drugs include PRO-542. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3301620 | 9.08 | Kd | 0.83 | Clinical |
| CHEMBL4281745 | 9.08 | IC50 | 0.84 | Preclinical |
| CHEMBL5204063 | 8.82 | IC50 | 1.5 | Preclinical |
| CHEMBL4575700 | 8.77 | EC50 | 1.7 | Preclinical |
| CHEMBL4644236 | 8.6 | IC50 | 2.53 | Preclinical |
| CHEMBL4289957 | 8.55 | IC50 | 2.82 | Preclinical |
| CHEMBL223228 | 8.46 | IC50 | 3.5 | Approved |
| CHEMBL440999 | 8.21 | IC50 | 6.1 | Preclinical |
| CHEMBL4474461 | 8.15 | EC50 | 7.1 | Preclinical |
| CHEMBL4579547 | 7.9 | EC50 | 12.5 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 32 | 65 | 6.2 |
| assay format | 18 | 45 | 6.4 |
| single protein format | 16 | 408 | 4.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |